The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

Carrie Underwood probably had a vision of how her version of “America the Beautiful” would be received after accepting Donald Trump’s invitation to perform at his Jan. 20 inauguration. The majestic views of the Capitol overlooking the crowds and singing a patriotic song were likely what the 41-year-old country singer had in mind — instead, it …

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than $200 billion over a decade.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of federal price negotiations, which are scheduled to begin this year, with resulting bargained prices going into effect in 2027.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.

The U.S. government named 15 drugs that will be subject to the second round of price negotiations by Medicare, including Ozempic and Wegovy, the drugs at the center of the weight-loss craze. The Biden administration said the drugs account for $41 billion in annual Medicare spending,